RVVTF

Revive Therapeutics (PK) Stock Price

0.228
0.01471 (6.9%)
0.228
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Revive Therapeutics Ltd (PK) RVVTF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.01471 6.9% 0.228 13:00:11
Open Price Low Price High Price Close Price Previous Close
0.2293 0.205 0.2332 0.21329
Bid Price Ask Price Spread News
0.227 0.2391 0.0121 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
961 4,603,087 $ 0.227104 $ 1,045,380 2,122,309 0.0173 - 0.50
Last Trade Time Type Quantity Stock Price Currency
13:21:29 formt 500 $ 0.227 USD

Revive Therapeutics (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 49.54M 217.29M - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
2.89M $ - 0.00% - -

more financials information »

Revive Therapeutics (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RVVTF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.1550.23320.153760.18993314,178,4520.07347.1%
1 Month0.1280.23320.1280.1730782,262,9840.1078.13%
3 Months0.210.238250.12610.18376992,035,4130.0188.57%
6 Months0.26650.500.120.22021753,345,297-0.0385-14.45%
1 Year0.020.500.01730.21771672,028,5690.2081,040.0%
3 Years0.20340.500.01730.2168777777,9550.024612.09%
5 Years0.52480.550.01730.2164821601,828-0.2968-56.55%

Revive Therapeutics (PK) Description

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com.


Your Recent History
USOTC
RVVTF
Revive The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.